Subretinal delivery of AAV2-mediated human erythropoietin gene is protective and safe in experimental diabetic retinopathy

Investigative Ophthalmology and Visual Science

Volumn 55, Issue 3, 2014, Pages 1519-1530

  Xu, Hua ^a,b,c   Zhang, Limei ^c   Gu, Limin ^a,b,c   Lu, Lixia ^a,c   Gao, Guangping ^d   Li, Weiye ^a,c,e   Xu, Guoxu ^f   Wang, Juan ^a,c   Gao, Furong ^a,c   Xu, Jing Ying ^a,c   Yao, Jun ^a   Wang, Fang ^a   Zhang, Jingfa ^a,c   Xu, Guo Tong ^a,b,c  

^a TENTH PEOPLE S HOSPITAL OF TONGJI UNIVERSITY   (China)

^b TONGJI UNIVERSITY   (China)

^c TONGJI UNIVERSITY SCHOOL OF MEDICINE   (China)

^d UNIVERSITY OF MASSACHUSETTS BOSTON   (United States)

^e DREXEL UNIVERSITY COLLEGE OF MEDICINE   (United States)

^f THE SECOND AFFILIATED HOSPITAL OF SOOCHOW UNIVERSITY   (China)

Author keywords

Aav; Diabetic retinopathy; Erythropoietin; Gene therapy; Safety

Indexed keywords

ERYTHROPOIETIN; PARVOVIRUS VECTOR;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; BLOOD RETINA BARRIER; CELL COUNT; CELL DEATH; CELL ISOLATION; CELL VIABILITY; COLONY FORMING UNIT E; CONFOCAL MICROSCOPY; CONTROLLED STUDY; DIABETIC RETINOPATHY; DRUG DELIVERY SYSTEM; ELECTRORETINOGRAPHY; ENZYME LINKED IMMUNOSORBENT ASSAY; ERYTHROPOIETIN GENE; FLUORESCENCE ANGIOGRAPHY; GENE; HEMATOCRIT; HISTOLOGY; HUMAN; HUMAN CELL; MALE; MICROSCOPY; MOUSE; NEUROPROTECTION; NICK END LABELING; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; RAT; RETINAL THICKNESS; SUBRETINAL DELIVERY SYSTEM; VIRAL GENE THERAPY;

AAV; DIABETIC RETINOPATHY; ERYTHROPOIETIN; GENE THERAPY; SAFETY;

ANIMALS; APOPTOSIS; BLOOD-RETINAL BARRIER; CELLS, CULTURED; DIABETES MELLITUS, EXPERIMENTAL; DIABETIC RETINOPATHY; DOSE-RESPONSE RELATIONSHIP, DRUG; ELECTRORETINOGRAPHY; ENZYME-LINKED IMMUNOSORBENT ASSAY; ERYTHROPOIETIN; FOLLOW-UP STUDIES; GENETIC THERAPY; HUMANS; INTRAVITREAL INJECTIONS; MALE; MICE; MICE, INBRED C57BL; RATS; RATS, SPRAGUE-DAWLEY; RETINA; TIME FACTORS; TREATMENT OUTCOME;

EID: 84896328104     PISSN: 01460404     EISSN: 15525783     Source Type: Journal    
DOI: 10.1167/iovs.13-13155     Document Type: Article

References (62)

1. Gardner TW, Antonetti DA, Barber AJ, LaNoue KF, Levison SW. Diabetic retinopathy: more than meets the eye. Surv Ophthalmol. 2002;47(suppl 2):S253-S262.
2. Kollias AN, Ulbig MW. Diabetic retinopathy: early diagnosis and effective treatment. Dtsch Arztebl Int. 2010;107:75-83, quiz 84.
3. Simo R, Hernandez C. Advances in the medical treatment of diabetic retinopathy. Diabetes Care. 2009;32:1556-1562.
4. Yasukawa T, Tabata Y, Kimura H, Ogura Y. Recent advances in intraocular drug delivery systems. Recent Pat Drug Deliv Formul. 2011;5:1-10.
5. Chung EJ, Kang SJ, Koo JS, Choi YJ, Grossniklaus HE, Koh HJ. Effect of intravitreal bevacizumab on vascular endothelial growth factor expression in patients with proliferative diabetic retinopathy. Yonsei Med J. 2011;52:151-157.
6. Nicholson BP, Schachat AP. A review of clinical trials of anti- VEGF agents for diabetic retinopathy. Graefes Arch Clin Exp Ophthalmol. 2010;248:915-930.
7. Mitchell P. A systematic review of the efficacy and safety outcomes of anti-VEGF agents used for treating neovascular age-related macular degeneration: comparison of ranibizumab and bevacizumab. Curr Med Res Opin. 2011;27:1465-1475.
8. Cheung N, Mitchell P, Wong TY. Diabetic retinopathy. Lancet. 2010;376:124-136.
9. Lieth E, Gardner TW, Barber AJ, Antonetti DA. Retinal neurodegeneration: early pathology in diabetes. Clin Experiment Ophthalmol. 2000;28:3-8.
10. Barber AJ. A new view of diabetic retinopathy: a neurodegenerative disease of the eye. Prog Neuropsychopharmacol Biol Psychiatry. 2003;27:283-290.
11. Whitmire W, Al-Gayyar MM, Abdelsaid M, Yousufzai BK, El- Remessy AB. Alteration of growth factors and neuronal death in diabetic retinopathy: what we have learned so far. Mol Vis. 2011;17:300-308.
12. Marti HH, Wenger RH, Rivas LA, et al. Erythropoietin gene expression in human, monkey and murine brain. Eur J Neurosci. 1996;8:666-676.
13. Hernandez C, Fonollosa A, Garcia-Ramirez M, et al. Erythropoietin is expressed in the human retina and it is highly elevated in the vitreous fluid of patients with diabetic macular edema. Diabetes Care. 2006;29:2028-2033.
14. Juul SE, Yachnis AT, Christensen RD. Tissue distribution of erythropoietin and erythropoietin receptor in the developing human fetus. Early Hum Dev. 1998;52:235-249.
15. Zhang J, Wu Y, Jin Y, et al. Intravitreal injection of erythropoietin protects both retinal vascular and neuronal cells in early diabetes. Invest Ophthalmol Vis Sci. 2008;49: 732-742.
16. Zhu B, Wang W, Gu Q, Xu X. Erythropoietin protects retinal neurons and glial cells in early-stage streptozotocin-induced diabetic rats. Exp Eye Res. 2008;86:375-382.
17. Zhang JF, Wu YL, Xu JY, et al. Pharmacokinetic and toxicity study of intravitreal erythropoietin in rabbits. Acta Pharmacol Sin. 2008;29:1383-1390.
18. Li W, Sinclair SH, Xu GT. Effects of intravitreal erythropoietin therapy for patients with chronic and progressive diabetic macular edema. Ophthalmic Surg Lasers Imaging. 2010;41: 18-25.
19. Jager RD, Aiello LP, Patel SC, Cunningham ET Jr. Risks of intravitreous injection: a comprehensive review. Retina. 2004; 24:676-698.
20. Stieger K, Mendes-Madeira A, Meur GL, et al. Oral administration of doxycycline allows tight control of transgene expression: a key step towards gene therapy of retinal diseases. Gene Ther. 2007;14:1668-1673.
21. Ribatti D, Vacca A, Roccaro AM, Crivellato E, Presta M. Erythropoietin as an angiogenic factor. Eur J Clin Invest. 2003; 33:891-896.
22. Watanabe D. [Erythropoietin as a retinal angiogenic factor in proliferative diabetic retinopathy]. Nihon Ganka Gakkai Zasshi. 2007;111:892-898.
23. Watanabe D, Suzuma K, Matsui S, et al. Erythropoietin as a retinal angiogenic factor in proliferative diabetic retinopathy. N Engl J Med. 2005;353:782-792.
24. Amado D, Mingozzi F, Hui D, et al. Safety and efficacy of subretinal readministration of a viral vector in large animals to treat congenital blindness. Sci Transl Med. 2010;2:21ra16.
25. Simonelli F, Maguire AM, Testa F, et al. Gene therapy for Leber's congenital amaurosis is safe and effective through 1.5 years after vector administration. Mol Ther. 2010;18:643-650.
26. Lebherz C, Auricchio A, Maguire AM, et al. Long-term inducible gene expression in the eye via adeno-associated virus gene transfer in nonhuman primates. Hum Gene Ther. 2005;16:178-186.
27. Buch PK, Bainbridge JW, Ali RR. AAV-mediated gene therapy for retinal disorders: from mouse to man. Gene Ther. 2008;15: 849-857.
28. Roy K, Stein L, Kaushal S. Ocular gene therapy: an evaluation of recombinant adeno-associated virus-mediated gene therapy interventions for the treatment of ocular disease. Hum Gene Ther. 2010;21:915-927.
29. Colella P, Auricchio A. AAV-mediated gene supply for treatment of degenerative and neovascular retinal diseases. Curr Gene Ther. 2010;10:371-380.
30. Lai CM, Shen WY, Brankov M, et al. Long-term evaluation of AAV-mediated sFlt-1 gene therapy for ocular neovascularization in mice and monkeys. Mol Ther. 2005;12:659-668.
31. Bainbridge JW, Smith AJ, Barker SS, et al. Effect of gene therapy on visual function in Leber's congenital amaurosis. N Engl J Med. 2008;358:2231-2239.
32. Cideciyan AV, Aleman TS, Boye SL, et al. Human gene therapy for RPE65 isomerase deficiency activates the retinoid cycle of vision but with slow rod kinetics. Proc Natl Acad Sci U S A. 2008;105:15112-15117.
33. Maguire AM, Simonelli F, Pierce EA, et al. Safety and efficacy of gene transfer for Leber's congenital amaurosis. N Engl J Med. 2008;358:2240-2248.
34. Auricchio A, Rivera VM, Clackson T, et al. Pharmacological regulation of protein expression from adeno-associated viral vectors in the eye. Mol Ther. 2002;6:238-242.
35. Stieger K, Le Meur G, Lasne F, et al. Long-term doxycyclineregulated transgene expression in the retina of nonhuman primates following subretinal injection of recombinant AAV vectors. Mol Ther. 2006;13:967-975.
36. Buemi M, Caccamo C, Nostro L, Cavallaro E, Floccari F, Grasso G. Brain and cancer: the protective role of erythropoietin. Med Res Rev. 2005;25:245-259.
37. Latini R, Brines M, Fiordaliso F. Do non-hemopoietic effects of erythropoietin play a beneficial role in heart failure? Heart Fail Rev. 2008;13:415-423.
38. Monge Naldi A, Gassmann M, Bodmer D. Erythropoietin but not VEGF has a protective effect on auditory hair cells in the inner ear. Cell Mol Life Sci. 2009;66:3595-3599.
39. Moore EM, Bellomo R, Nichol AD. Erythropoietin as a novel brain and kidney protective agent. Anaesth Intensive Care. 2011;39:356-372.
40. Chateauvieux S, Grigorakaki C, Morceau F, Dicato M, Diederich M. Erythropoietin, erythropoiesis and beyond. Biochem Pharmacol. 2011;82:1291-1303.
41. Mitsuhashi J, Morikawa S, Shimizu K, Ezaki T, Yasuda Y, Hori S. Intravitreal injection of erythropoietin protects against retinal vascular regression at the early stage of diabetic retinopathy in streptozotocin-induced diabetic rats. Exp Eye Res. 2013;106: 64-73.
42. Zhang J, Xu G, Zhang L, et al. A modified histoimmunochemistry- assisted method for in situ RPE evaluation. Front Biosci (Elite Ed). 2012;4:1571-1581.
43. McClements ME, MacLaren RE. Gene therapy for retinal disease. Transl Res. 2013;161:241-254.
44. Lebherz C, Maguire A, Tang W, Bennett J, Wilson JM. Novel AAV serotypes for improved ocular gene transfer. J Gene Med. 2008;10:375-382.
45. Igarashi T, Miyake K, Masuda I, Takahashi H, Shimada T. Adenoassociated vector (type 8)-mediated expression of soluble Flt-1 efficiently inhibits neovascularization in a murine choroidal neovascularization model. Hum Gene Ther. 2010;21:631-637.
46. Yu H, Chen L, Jiang J. Administration of pigment epitheliumderived factor delivered by adeno-associated virus inhibits blood-retinal barrier breakdown in diabetic rats. Mol Vis. 2011; 16:2384-2394.
47. Lai CC, Wu WC, Chen SL, et al. Recombinant adeno-associated virus vector expressing angiostatin inhibits preretinal neovascularization in adult rats. Ophthalmic Res. 2005;37:50-56.
48. Zhang J, Hu LM, Xu G, et al. Anti-VEGF effects of intravitreal erythropoietin in early diabetic retinopathy. Front Biosci (Elite Ed). 2010;2:912-927.
49. Shen J, Wu Y, Xu JY, et al. ERK- and Akt-dependent neuroprotection by erythropoietin (EPO) against glyoxal-AGEs via modulation of Bcl-xL, Bax, and BAD. Invest Ophthalmol Vis Sci. 2010;51:35-46.
50. Chu Q, Zhang J, Wu Y, et al. Differential gene expression pattern of diabetic rat retinas after intravitreal injection of erythropoietin. Clin Experiment Ophthalmol. 2011;39:142-151.
51. Lei X, Zhang J, Shen J, et al. EPO attenuates inflammatory cytokines by Muller cells in diabetic retinopathy. Front Biosci (Elite Ed). 2011;3:201-211.
52. Auricchio A, Kobinger G, Anand V, et al. Exchange of surface proteins impacts on viral vector cellular specificity and transduction characteristics: the retina as a model. Hum Mol Genet. 2001;10:3075-3081.
53. Rolling F. Recombinant AAV-mediated gene transfer to the retina: gene therapy perspectives. Gene Ther. 2004;11(suppl 1):S26-S32.
54. Adamson JW. Regulation of red blood cell production. Am J Med. 1996;101:4S-6S.
55. Haribalaganesh R, Sheikpranbabu S, Banumathi E, Gurunathan S. Pigment epithelium-derived factor inhibits erythropoietininduced retinal endothelial cell angiogenesis by suppression of PI3K/Akt pathway. Exp Eye Res. 2010;90:726-733.
56. Tong Z, Yang Z, Patel S, et al. Promoter polymorphism of the erythropoietin gene in severe diabetic eye and kidney complications. Proc Natl Acad Sci U S A. 2008;105:6998-7003.
57. Song BJ, Cai H, Tsai JC, Chang S, Forbes M, Del Priore LV. Intravitreal recombinant human erythropoietin: a safety study in rabbits. Curr Eye Res. 2008;33:750-760.
58. Lagreze WA, Feltgen N, Bach M, Jehle T. Feasibility of intravitreal erythropoietin injections in humans. Br J Ophthalmol. 2009;93:1667-1671.
59. Baffi J, Byrnes G, Chan CC, Csaky KG. Choroidal neovascularization in the rat induced by adenovirus mediated expression of vascular endothelial growth factor. Invest Ophthalmol Vis Sci. 2000;41:3582-3589.
60. Wang F, Rendahl KG, Manning WC, Quiroz D, Coyne M, Miller SS. AAV-mediated expression of vascular endothelial growth factor induces choroidal neovascularization in rat. Invest Ophthalmol Vis Sci. 2003;44:781-790.
61. Chen J, Connor KM, Aderman CM, Smith LE. Erythropoietin deficiency decreases vascular stability in mice. J Clin Invest. 2008;118:526-533.
62. Chen J, Connor KM, Aderman CM, Willett KL, Aspegren OP, Smith LE. Suppression of retinal neovascularization by erythropoietin siRNA in a mouse model of proliferative retinopathy. Invest Ophthalmol Vis Sci. 2009;50:1329-1335.